News

20 Presentations Highlighting Cellvizio’s® Clinical Value in Evaluating IBDs and Pancreatic Cysts at DDW 2018

31 May 2018

Twenty accepted abstracts demonstrate growing clinical adoption and recognition of Cellvizio as a necessary tool for real-time optical biopsy in multiple gastrointestinal indications

Mauna Kea Technologies today announced 20 abstracts supporting Cellvizio® to be presented at the Digestive Disease Week (DDW) Conference, being held on June 2-5 in Washington, D.C. These abstracts focus on Barrett’s esophagus, Inflammatory Bowel Disease / Syndrome (IBD / IBS), pancreatic cyst and other gastrointestinal diseases. This year marks a turning point for endomicroscopy with Cellvizio®, as studies are now focused on patient management, the technology having already proven its diagnostic performance in previous years.

“Real-time in vivo optical biopsy with Cellvizio is once again taking center stage at the Digestive Disease Week® as evidenced by the large number of high quality studies presented this year. Endomicroscopy is also been recognized as a key technology for the assessment of pancreatic diseases as Dr Krishna will present in his American Gastroenterological Association invited lecture on CLE.” said Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea Technologies. “We’re excited to see that most studies focus on demonstrating significant impact on patient management, positioning Cellvizio as a key driver for improved outcomes and reduced healthcare costs in multiple applications such as pancreatic lesions or Inflammatory Bowel Disease, two conditions in great need of better solutions. Our new sales team in the US will surely benefit from this strong momentum.”

Highlighted Featured Presentations:

  • A Large Single Center Experience Using EUS-Guided Needle Based Confocal Laser Endomicroscopy For The Management Of Pancreatic Cystic Lesions
    Presentation # 156
    Saturday, June 2; at 2:45 – 3:00 p.m. ET
    Room 144
    Presenting Author: Somashekar G. Krishna, The Ohio State University Medical Center

  • Needle Based Confocal Laser Endomicroscopy: The Impact On Diagnosis And Management Of Pancreatic Cystic Lesions
    Presentation # 184
    Saturday, June 2; at 4:14 – 4:28 p.m. ET
    Room 144
    Presenting Author: Maxime Palazzo, Hôpital Beaujon, Clichy, France

  • Confocal Laser Endomicroscopy
    Presentation # Sp6
    Saturday, June 2; at 8:22 – 8:44 p.m. ET
    Room 145B
    Presenting Author: Somashekar G. Krishna, The Ohio State University Medical Center

  • Food Intolerance In IBS Is Due To An Eosinophil Activation Syndrome?
    Presentation # 289
    Sunday, June 3; at 11:15 – 11:30 a.m. ET
    Hall C
    Presenting Authors: Theresa Pflaum & Annette Fritscher-Ravens, University Hospital Schleswig- Holstein, Kiel, Kiel, Germany

Featured Poster Session:

  • Improving Patient Outcomes With Personalized Inflammatory Bowel Disease Care Using Probe- Based Confocal Laser Endomicroscopy
    Poster Su1917
    Sunday, June 3; at 12:00 – 2:00 p.m. ET
    Hall C
    Presenting Authors: Ali M. Ridha & Julia J. Liu, University of Arkansas for Medical Sciences

  • IBS Patients With Reaction To Wheat And Other Food Antigens Proven On Confocal Laser Endomicroscopy (CLE) Have Prognostic Parameters For Disease, Irrespective Of The Antigen They React To
    Poster Mo1050
    Monday, June 4; at 12:00 – 2:00 p.m. ET
    Hall C
    Presenting Authors: Marie Moesinger & Annette Fritscher-Ravens, University Hospital Schleswig- Holstein, Kiel, Kiel, Germany

  • Confocal Endomicroscopy (CLE) Based Double Blind Randomized Controlled Cross-Over Study Provides Objective Measurement Of Food Sensitivity In IBS Patients, Their Somatization, Anxiety And Depression
    Poster Mo1052
    Monday, June 4; at 12:00 – 2:00 p.m. ET
    Hall C
    Presenting Authors: Zino Ruchay & Annette Fritscher-Ravens, University Hospital Schleswig-Holstein, Kiel, Kiel, Germany

    You are also invited to visit us at booth #2145 in the Exhibit Hall.

Latest News

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® 

Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® 

Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024

Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024